Benzodiazepines for pediatric epilepsies and their risks in a cohort within the French health care data
Résumé
Objective: The management of antiseizure treatment in patients with epilepsy relies on the benefit–risk ratio. Data on antiseizure medication (ASM) use in children are limited. We described antiseizure medication use in children with epilepsy (CwE) in France, with a focus on the chronic use of benzodiazepines and related implications. Methods: We conducted a 5‐year cohort study from January 2012, using data from the French national health care data system (Système National des Données de Santé). We included CwE identified through International Classification of Diseases, 10th Revision codes and medications from January 2012 to December 2015 and followed them until December 2016. We described ASMs and assessed whether the risk of initiating a polytherapy after a bitherapy depends on whether benzodiazepine was included in the bitherapy. Results: We identified 62 885 CwE. Valproate was the most reimbursed ASM (40%), followed by lamotrigine (17.6%), levetiracetam (9.3%), clobazam (6.1%), and carbamazepine (5.8%). Prescriptions were initiated at the hospital in 74.5% of CwE. We observed a decrease in the number of CwE with at least one benzodiazepine reimbursement from 15.3% in 2013 to 10.1% in 2016 ( p < .0001). The prevalence of CwE with levetiracetam reimbursements increased, whereas that of CwE with valproate decreased. A switch from a bitherapy to a polytherapy was more likely when the bitherapy included a benzodiazepine (subdistribution hazard ratio [sHR] = 1.20 [1.03–1.39]). Significance: The prevalence of CwE with at least one benzodiazepine reimbursement decreased during the study period. Benzodiazepines were associated with an increased use of subsequent ASM polytherapy.
Fichier principal
Risks of benzodiazepines for pediatric epilepsy_Manuscript.pdf (101.43 Ko)
Télécharger le fichier
EPIBENZO_fig-1.tiff (1.49 Mo)
Télécharger le fichier
EPIBENZO_fig-2.tiff (675.98 Ko)
Télécharger le fichier
EPIBENZO_fig-3.tiff (349.05 Ko)
Télécharger le fichier
EPIBENZO_fig-4.tiff (1.03 Mo)
Télécharger le fichier
EPIBENZO_supp-material-1 (1).docx (36.21 Ko)
Télécharger le fichier
EPIBENZO_supp-material-1.docx (36.21 Ko)
Télécharger le fichier
EPIBENZO_supp-material-2 (1).docx (742.8 Ko)
Télécharger le fichier
EPIBENZO_supp-material-2.docx (742.8 Ko)
Télécharger le fichier
| Origine | Fichiers produits par l'(les) auteur(s) |
|---|